IV期ROS1重排非小细胞肺癌脑转移发生率及克唑替尼治疗期间中枢神经系统进展率
该回顾性研究纳入2008年至2017年间579例IV期NSCLC患者,其中ROS1阳性33例、ALK阳性115例。初治ROS1阳性患者脑转移发生率为36%,与ALK阳性(34%)及其他驱动基因间无显著差异;克唑替尼治疗中ROS1阳性患者中位PFS为11个月,CNS为首个且唯一进展部位者占47%。
要点
- 初治IV期ROS1阳性NSCLC脑转移发生率为36%,与ALK阳性(34%)及其他驱动基因无显著差异
- 克唑替尼治疗中ROS1阳性患者CNS为首个且唯一进展部位者占47%
- ROS1阳性与ALK阳性患者中位PFS分别为11个月和8个月,差异无统计学意义(p=0.304)
核心结论
- 初治IV期ROS1阳性NSCLC脑转移常见,但发生率与其他驱动基因队列无差异。
- 克唑替尼治疗中CNS是ROS1阳性患者常见的首个进展部位。
- 研究强调开发可穿透CNS的酪氨酸激酶抑制剂对ROS1阳性NSCLC患者的重要性。
研究设计与样本
- 回顾性综述,纳入2008年6月至2017年12月间579例IV期NSCLC患者。
- 记录脑转移及驱动基因状态(ROS1、ALK、EGFR、KRAS、BRAF等)。
- 在服用克唑替尼的ROS1阳性和ALK阳性患者中测量无进展生存期和至CNS进展时间。
主要发现
- 初治IV期ROS1阳性患者脑转移发生率为36%(12/33),ALK阳性为34%(39/115)。
- ROS1、ALK、EGFR、KRAS、BRAF或其他突变间脑转移发生率无统计学显著差异。
- 19例ROS1阳性和83例ALK阳性患者有完整生存数据,中位PFS分别为11个月和8个月(p=0.304)。
- CNS作为首个且唯一进展部位在ROS1阳性患者中占47%(9/19),ALK阳性中占33%(28/83),组间无统计学显著差异(p=0.610)。
临床怎么用
- 对初治IV期ROS1阳性NSCLC患者应关注脑转移筛查。
- 克唑替尼治疗期间需警惕CNS作为首个进展部位,加强CNS监测。
- 支持优先开发或选用可穿透CNS的酪氨酸激酶抑制剂。
局限性
- 回顾性研究设计。
- ROS1阳性患者样本量较小(33例),其中仅19例有完整生存数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in stage IV ROS1-positive NSCLC and the rate of CNS progression during crizotinib therapy. METHODS: A retrospective review of 579 patients with stage IV NSCLC between June 2008 and December 2017 was performed. Brain metastases and oncogene status (ROS1, ALK receptor tyrosine kinase gene [ALK], EGFR, KRAS, BRAF, and others) were recorded. We measured progression-free survival and time to CNS progression in ROS1-positive and ALK-positive patients who were taking crizotinib. RESULTS: We identified 33 ROS1-positive and 115 ALK-positive patients with stage IV NSCLC. The incidences of brain metastases for treatment-naive, stage IV ROS1-positive and ALK-positive NSCLC were 36% (12 of 33) and 34% (39 of 115), respectively. There were no statistically significant differences in incidence of brain metastases across ROS1, ALK, EGFR, KRAS, BRAF, or other mutations. Complete survival data were available for 19 ROS1-positive and 83 ALK-positive patients. The median progression-free survival times for ROS1-positive and ALK-positive patients were 11 and 8 months, respectively (p = 0.304). The CNS was the first and sole site of progression in 47% of ROS1-positive (nine of 19) and 33% of ALK-positive (28 of 83) patients, with no statistically significant differences between these groups (p = 0.610). CONCLUSIONS: Brain metastases are common in treatment-naive stage IV ROS1-positive NSCLC, though the incidence does not differ from that in other oncogene cohorts. The CNS is a common first site of progression in ROS1-positive patients who are taking crizotinib. This study reinforces the importance of developing CNS-penetrant tyrosine kinase inhibitors for patients with ROS1-positive NSCLC.
引用
- Patil T, Smith DE, Bunn PA, et al. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018. PMID: 29981925. doi:10.1016/j.jtho.2018.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。